Answers are grounded in this paper and cite their sources.
Background: There are limited long-term clinical outcome data comparing first-generation (1G) versus second-generation (2G) drug-eluting stents (DES) in patients with single-vessel disease (SVD).We sought to compare the efficacy and safety of 1G-and 2G-DES in SVD patients who underwent successful percutaneous coronary intervention (PCI) over 10 years of clinical follow-up.Methods: A total of 2,312 consecutive patients with SVD who underwent PCI with 1G-DES (paclitaxel-or sirolimus-eluting stents, n = 811) or 2G-DES (zotarolimus [Endeavor, Endeavor Resolute]-or everolimus-eluting stents [Promus Element, Xience], n = 1,082) were enrolled.After propensity score matching, 2 matched groups (538 pairs) were generated.Study endpoints included individual and composite clinical outcomes through 10 years.Results: During the 10-year follow-up, the 2G-DES group had lower incidences of myocardial infarction (MI; hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.22-0.92;P = 0.028) and target lesion revascularization (TLR; HR, 0.54; 95% CI, 0.32-0.91;P = 0.021) than the 1G-DES group.Rates of total death, cardiac death, non-target vessel revascularization, stroke, major adverse cardiac events, and major adverse cardiac and cerebrovascular events were similar between groups.Conclusions: In our single-center, all-comer registry, 2G-DES were associated with lower incidence rates of MI and TLR compared to 1G-DES in SVD patients over 10 years of followup, indicating a safer and more durable effect than 1G-DES.
No takes yet. Share an insight, caveat, or question.
Byun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: